Connect with us

Technology

Research Payloads to Support Long-Duration Spaceflight and Improve Osteoarthritis and Cancer Treatment Return From Space Station

Published

11 months ago

on

NASA’s latest SpaceX resupply mission to the space station returns with ISS National Lab-sponsored projects advancing biomedical R&D, technology development, and physical sciences

KENNEDY SPACE CENTER, Fla., May 27, 2025 /PRNewswire/ — ELVIS is back. Samples from the Extant Life Volumetric Imaging System (ELVIS)—a new holographic microscope—have returned from the International Space Station (ISS). The samples splashed down off the coast of California alongside more than two dozen other investigations sponsored by the ISS National Laboratory®. Experiments returning on SpaceX’s 32nd commercial resupply services mission for NASA include a project to manufacture nanomaterials in space to treat osteoarthritis and cancer on Earth and several investigations funded by the U.S. National Science Foundation (NSF).

These are a few highlights of the investigations that returned to Earth for further study to benefit humanity:

Using innovative holographic technology, ELVIS delivers detailed 3D views of cellular life, allowing scientists to study the adaptability and resilience of life under extreme conditions. Findings could reveal how life might persist on distant moons and planets, potentially enhancing the search for life beyond Earth. Portland State University, in collaboration with NASA’s Jet Propulsion Laboratory in Southern California and Teledyne Brown Engineering, Inc., tested the advanced microscope system onboard the orbiting laboratory. A collection of samples examined on the space station returned for further analysis so the team can determine ELVIS’ next steps in space.

Researchers from the University of Connecticut and Eascra Biotech, with support from Axiom Space, built on previous research to improve the production of innovative nanomaterials in space. Janus base nanomaterials (JBNs) are composed of synthetic molecules that self-assemble into structures resembling human DNA. The injectable nanomaterials could help regenerate cartilage in the joints of osteoarthritis patients and could be used to carry cancer drugs into hard-to-penetrate solid tumors. The team’s groundbreaking research is featured in the most recent issue of Upward, official magazine of the ISS National Lab.

A project that is part of a series of investigations developed by the U.S. Air Force and the U.S. Air Force Academy, in partnership with Rhodium Scientific, examined how genetically modified tomato plants grow in the space environment. The team aimed to better understand how genetic modifications and gene expression changes influence root and shoot development. The researchers will compare results from this experiment with those from investigations on the Polaris Dawn and NASA’s SpaceX Crew-9 missions, which featured the same Rhodium plant growth hardware. Findings could provide insights into the production of crops on long-duration space missions or in high-radiation environments.

An experiment from Sophie’s BioNutrients, supported by BioServe Space Technologies, aims to develop plant-based, protein-rich alternatives to meat and seafood using microalgae. The investigation examined how microgravity affects protein yields in microalgae that require nutrition from organic compounds to grow. Results could provide insights into the fundamental mechanisms of microalgae cell growth, metabolism, and protein production. In addition to serving as a food source on long-duration spaceflight missions, microalgae could also be used in life support systems and to provide oils for fuel production.

Four investigations funded by NSF seek to advance fundamental science with valuable applications, continuing a strong, multiyear collaboration between NSF and the ISS National Lab. One of these projects, from Lehigh University, could enable the next generation of portable microfluidic devices that use bioseparation for virus detection. This process, which separates particles from fluids, relies on thermophoresis—the tendency of particles suspended in a solution to move from hot to cold regions along a temperature gradient. Bioseparation can be used in medical lab tests to detect the presence of a virus by separating virus particles from bodily fluids in samples.

To learn more about these projects and others that launched on this resupply mission, please visit our launch page. For additional information on the ISS National Lab and its mission to enable R&D in space for the benefit of humanity, see our website.

Download a high-resolution image for this release: NASA’s SpaceX CRS-32

About the International Space Station (ISS) National Laboratory:
The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory® allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space® (CASIS®) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website.

As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page.

Media Contact:

Patrick O’Neill 

904-806-0035 

PONeill@ISSNationalLab.org

 

International Space Station (ISS) National Laboratory

Managed by the Center for the Advancement of Science in Space® (CASIS®)

1005 Viera Blvd., Suite 101, Rockledge, FL 32955 • 321.253.5101 • www.ISSNationalLab.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/research-payloads-to-support-long-duration-spaceflight-and-improve-osteoarthritis-and-cancer-treatment-return-from-space-station-302466060.html

SOURCE International Space Station National Lab

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

MATSON ANNOUNCES ADDITION OF 3 MILLION SHARES TO EXISTING SHARE REPURCHASE PROGRAM AND QUARTERLY DIVIDEND OF $0.36 PER SHARE

Published

37 minutes ago

on

April 23, 2026

By

HONOLULU, April 23, 2026 /PRNewswire/ — The Board of Directors of Matson, Inc. (NYSE: MATX), a leading U.S. carrier in the Pacific, approved adding three million shares to its existing share repurchase program and extending the program to December 31, 2029.  As of April 23, 2026, the existing share repurchase program had approximately 0.7 million shares remaining.  The Board also declared a second quarter dividend of $0.36 per common share.  The dividend will be paid on June 4, 2026 to all shareholders of record as of the close of business on May 7, 2026.

“We are pleased to announce an additional three million shares to our existing share repurchase program,” said Matt Cox, Matson’s Chairman and Chief Executive Officer.  “Since we commenced our share repurchase program in August 2021, we have repurchased approximately 14.3 million shares, or approximately 33% of the then outstanding shares, for a total cost of $1.3 billion.  Going forward, we will continue to be both disciplined and opportunistic in our capital allocation, and we remain committed to returning excess cash to shareholders to create additional shareholder value over the long-term.” 

Shares will be repurchased in the open market from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its common shares and general market conditions.  The Company may enter into Rule 10b5-1 plans to facilitate purchases under the program.  The repurchase program may be suspended or discontinued at any time.

About the Company

Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services.  Matson provides a vital lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia.  Matson also operates premium, expedited services from China to Long Beach, California, which includes cargo from other Asia origins, provides services to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Alaska to Asia.  The Company’s fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and barges.  Matson Logistics, established in 1987, extends the geographic reach of Matson’s transportation network throughout North America and Asia.  Its integrated logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, supply chain management, and freight forwarding to Alaska.  Additional information about the Company is available at www.matson.com.

Forward Looking Statements

Statements in this news release that are not historical facts are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement, including but not limited to, statements about capital allocation plans, the timing, manner and volume of repurchases of common shares pursuant to the repurchase program, and use of excess cash.  These forward-looking statements are not guarantees of future performance.  This release should be read in conjunction with our Annual Report on Form 10-K and our other filings with the SEC through the date of this release, which identify important factors that could affect the forward-looking statements in this release.  We do not undertake any obligation to update our forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/matson-announces-addition-of-3-million-shares-to-existing-share-repurchase-program-and-quarterly-dividend-of-0-36-per-share-302752377.html

SOURCE Matson, Inc.

Continue Reading

Technology

Accord Specialty Pharmacy Named Finalist in MMIT’s 11th Annual Retail Specialty Pharmacy Patient Choice Awards

Published

2 hours ago

on

April 23, 2026

By

ORLANDO, Fla., April 23, 2026 /PRNewswire/ — Accord Specialty Pharmacy, an independent specialty pharmacy serving patients across multiple states, has been named a finalist in the MMIT Patient Choice Awards, a recognition based on patient-reported satisfaction and experience.

Accord was selected as the only independent pharmacy among finalists in its category, alongside national pharmacy organizations such as Walgreens Specialty Pharmacy and Walmart Specialty Pharmacy. This distinction highlights the company’s commitment to delivering personalized, high-touch care for patients managing complex and chronic conditions.

The MMIT Patient Choice Awards recognize specialty pharmacies that demonstrate excellence in patient satisfaction, service quality, and overall care experience. Finalists are determined based on direct patient feedback, making the recognition a meaningful reflection of the trust patients place in their pharmacy providers.

“Being recognized alongside national organizations and as the only independent finalist validates our belief that personalized, patient-centered care drives better outcomes. We are building a model that combines clinical depth, national reach, and operational flexibility to better serve patients, providers, and partners.” said AJ Patel, Founder and Pharmacy Manager of Accord Specialty Pharmacy.

Accord Specialty Pharmacy supports patients across complex specialty categories, including oncology, rare disease, and infusion, through a clinically driven, high-touch care model designed to improve access, adherence, and outcomes. The company’s approach emphasizes personalized support, responsive care coordination, and strong clinical engagement to help patients navigate complex therapies more effectively. With a growing national footprint and multi-state licensure, Accord is positioned to support patients, providers, and partners across diverse markets.

For more information, visit MMIT Announces Finalists of the 11th Specialty Pharmacy Patient Choice Awards – MMITNetwork.

About Accord Specialty Pharmacy:

Accord Specialty Pharmacy is an ACHC-accredited, multi-state licensed independent specialty pharmacy located in Central Florida, dedicated to delivering high-quality, patient-centered care for individuals managing complex and chronic conditions. Through personalized support, clinical expertise, and a high-touch approach, Accord helps patients navigate every step of their treatment journey. Learn more at www.accordspecialty.com.

CONTACT: contact@accordspecialty.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accord-specialty-pharmacy-named-finalist-in-mmits-11th-annual-retail-specialty-pharmacy-patient-choice-awards-302752327.html

SOURCE Accord Specialty

Continue Reading

Technology

HAIVISION ANNOUNCES VOTING RESULTS FROM 2026 ANNUAL MEETING OF SHAREHOLDERS

Published

2 hours ago

on

April 23, 2026

By

MONTRÉAL, April 23, 2026 /CNW/ – Haivision Systems Inc. (“Haivision” or the “Company”) (TSX: HAI) is pleased to announce the voting results from its annual meeting of shareholders held today in a virtual format.

A total of approximately 45.97 % of the issued and outstanding common shares of Haivision were represented at the meeting.

Election of Directors

Each of the six nominated directors of Haivision was elected as director of the Company with the following results:

Director

Votes
For

% Votes
For

Votes
Against

% Votes
Against

Miroslav Wicha

11,110,245

99.26 %

82,583

0.74 %

Harvey Bienenstock

11,155,137

99.66 %

37,691

0.34 %

Robin M. Rush

11,121,855

99.37 %

70,973

0.63 %

Neil Hindle

10,794,005

96.44 %

398,823

3.56 %

Julie Tremblay

10,941,969

97.76 %

250,859

2.24 %

Lee K. Levy II

9,084,418

81.16 %

2,108,410

18.84 %

2.   Appointment of Auditors

Deloitte LLP were reappointed auditors of the Company for the ensuing year with 12,492,582 (98.84%) votes cast in favour and 146,406 (1.16%) votes withheld.

3.   Approval of the Unallocated Awards under the Company’s Equity Incentive Plan

The Company’s unallocated awards were approved with 8,710,347 (77.82%) votes cast in favour and 2,482,481 (22.18%) votes cast against.

4.   Reapproval of Company’s Shareholder Rights Plan

The Company’s shareholder rights plan was approved with 10,572,490 (94.46%) votes cast in favour and 620,338 (5.54%) votes cast against.

Final voting results on all matters voted on at the meeting will be filed under Haivision’s profile on SEDAR+ at www.sedarplus.ca.

About Haivision

Haivision is a leading global provider of mission-critical, real-time video streaming and visual collaboration solutions. Our connected cloud and intelligent edge technologies enable organizations globally to engage audiences, enhance collaboration, and support decision making. We provide high quality, low latency, secure, and reliable live video at a global scale. Haivision open sourced its award-winning SRT low latency video streaming protocol and founded the SRT Alliance to support its adoption. Awarded four Emmys® for Technology and Engineering from the National Academy of Television Arts and Sciences, Haivision continues to fuel the future of IP video transformation. Founded in 2004, Haivision is headquartered in Montreal and Chicago with offices, sales, and support located throughout the Americas, Europe, and Asia. Learn more at haivision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/haivision-announces-voting-results-from-2026-annual-meeting-of-shareholders-302752318.html

SOURCE Haivision Systems Inc.

Continue Reading

Trending